C&D Pharma introduces new treatments for non-communicable diseases in Uganda

UGANDA—Indian pharmaceutical company C&D Pharma has introduced three new medications to treat hypertension, diabetes, kidney disease, and cardiovascular conditions.

Launched at a well-attended symposium in Kampala, the products were showcased with the backing of Uganda’s Ministry of Health, Joint Medical Stores (JMS), and KAMCARE, highlighting a commitment to improving access to innovative, affordable therapies across Uganda.

The newly introduced fourth-generation therapies include Cliniplan Trio, Dairetin Family, and Daptide, with each product is designed to offer advanced management options for different chronic conditions.

Cliniplan Trio is a novel combination therapy for hypertension that effectively regulates high blood pressure while protecting vital organs like the heart, kidneys, brain, and eyes.

The Dairetin Family, which includes Diatrin M and Diatrin Trio, represents a breakthrough in diabetic care.

It enables stable blood sugar control and reduces the risk of complications associated with diabetes.

Meanwhile, Daptide offers a comprehensive approach for managing diabetes and hypertension, providing precise control to prevent complications affecting the heart, kidneys, and blood vessels.

Dr. Charles Olaro, Director of Curative Services at Uganda’s Ministry of Health, emphasized the urgency of addressing the prevalence of NCDs, especially in rural and underserved areas where access to healthcare remains limited.

According to Dr. Olaro, innovative treatments like these are essential to managing symptoms and preventing long-term complications that strain Uganda’s healthcare resources.

He added that with these advanced therapies, Uganda can take a meaningful step towards more effectively treating NCDs across the country.

Moreover, Dr. Olaro highlighted that these treatments improve patient health outcomes and reduce the “pill burden” on individuals and families struggling with prolonged treatment costs.

He noted that these medications are a step towards health equity, as they are designed to reach even the most remote communities, ensuring that all Ugandans have access to effective healthcare solutions.

Through partnerships with JMS and KAMCARE, C&D Pharma’s latest therapies are expected to transform Uganda’s healthcare landscape.

These organizations will play a key role in ensuring the medications’ availability in rural and underserved regions, aiming to bridge existing gaps in healthcare access.

Adding to these sentiments, Chirag Vora, Managing Director of C&D Pharma, shared his optimism about the impact of these therapies.

He noted that the high efficacy of these medications could significantly reduce Uganda’s healthcare burden, decreasing the demand for emergency care and long-term hospitalizations, which in turn could lead to more efficient allocation of healthcare resources.

 Vora further expressed C&D Pharma’s commitment to improving the health and well-being of Ugandans.

He expressed confidence that, with the Ministry of Health’s support and partnerships with JMS and KAMCARE, these innovative therapies would indeed make a substantial difference in the lives of countless people across Uganda.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.